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L
ipodystrophy (LD) is a well-defined
syndrome that affects many HIV patients
treated with highly active antiretroviral
therapy (HAART).1–4 This syndrome is a
progressive process that appears about 6 months
after HAART is begun and becomes clinically
significant after 1 year of therapy.5 It remains
controversial whether LD is more common in
patients taking protease inhibitor (PI)1,6–8 or
thymidine analogue9–11 containing therapy.
However, as antiretroviral therapy is usually given
in combination, the relative contribution of PI and
thymidine analogues in causing LD is unclear.9,12
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Purpose: During the 24-week PIILR study of protease inhibitor (PI) withdrawal,
improved lipids and reduction in intraabdominal visceral fat was seen, however,
there was also a loss of subcutaneous limb fat in patients with HIV-lipodystrophy
(LD). It was hypothesized that overall improvement in LD may require a longer period
of time off PIs. Method: Follow-up of patients randomized to stop or continue PI-
based therapy for 24 weeks, in a multicenter study, was continued for up to 120
weeks. Biochemistry and lipid parameters were assessed every 3 months. DEXA
and CT scans were performed annually. Limb fat, visceral adipose tissue, and the
lipodystrophy case definition score (LCDS) were used as indicators of LD severity.
Results: Forty-five male patients with baseline and week 120 body composition
data were assessed. There were no significant changes in the limb fat or visceral
adipose tissue (VAT) components of LD, with the exception of the LCDS (change
from baseline +5.79, p < .001). Control of viral replication was maintained and lipid
and glycemic parameters were unchanged over the 120-week follow-up. Linear
regression analysis showed on-study usage of stavudine was independently and
significantly correlated with both decreased limb fat mass and a higher LCDS.
Conclusion: Body composition or metabolic features of LD did not improve over 2
years of observation in patients remaining on predominantly PI-sparing therapy. LD
was adversely influenced by continued stavudine use. Key words: lipodystrophy,
thymidine analogues, protease inhibitors
Reversibility of LD has been evaluated in ran-
domized trials and cohorts using various methods
involving both PI switching7,8,13 and thymidine ana-
logue switching.11,14,15 These studies were conductedPROGRESSION OF LD WITH THYMIDINE ANALOGUE USE •M ARTIN ET AL. 193
over a relatively short time period and resulted in
beneficial alterations of metabolic parameters, but
only small changes in LD-related body composition.
Changes in body shape associated with HAART
therapy in a cohort of 277 patients who were fol-
lowed for 2 years indicated that the rate of progres-
sion of LD was greater in those patients treated with
stavudine (d4T) than those with zidovudine (ZDV).9
However, PI therapy in addition to nucleoside re-
verse transcriptase inhibitor (NRTI) treatment accel-
erated this rate of progression.9
There remains a need for further long-term in-
vestigations into possible alterations in anti-
retroviral-associated LD. The PIILR long-term fol-
low-up study involved a well-described cohort of
patients initially enrolled in a randomized con-
trolled trial of stopping or continuing PI-based
therapy. During the 24-week randomized phase of
the PIILR trial, abdominal fat decreased but so did
limb fat mass.8 Longer follow-up was undertaken
to determine if overall improvement in LD could
be achieved and to verify which factors influenced
changes in body composition.
METHOD
Study Population
This study involved the long-term follow-up of
patients with clinically assessed LD while on sup-
pressive HAART, who were enrolled in a random-
ized, multicenter study comparing the effect of PI
substitution with continued PI-based treatment. In
the original PIILR study,8 all patients continued
current nucleoside analogue therapy. Sixty percent
of patients were randomized to switch PI therapy
and 40% to continue. Switch group patients re-
placed PI(s) with open-label abacavir (300 mg twice
daily), nevirapine (200 mg daily for 2 weeks, then
200 mg twice daily), adefovir (60 mg daily, with L-
carnitine supplementation 500 mg daily) at
baseline and with hydroxyurea (500 mg twice
daily) from week 4, while continuing their existing
nucleoside analogues. This combination was se-
lected on the basis of concerns regarding the main-
tenance of  adequate viral suppression in exten-
sively pretreated patients who were discontinuing
effective PI therapy. In the original PIILR trial, 71%
of patients randomized to continue PI therapy
elected to switch to a non-protease regimen at
week 24, making this a cohort of predominantly PI-
sparing patients with clinically evident LD. After
week 24, changes to antiretroviral therapy were at
the discretion of the clinician and patient. During
the follow-up phase, patients attended for meta-
bolic and body scanning. Due to the logistics of
arranging continued body scanning at some sites,
not all patients had imaging data available. This
analysis comprises those participants who com-
pleted both the body composition and metabolic
measurements to week 120.
Assessments
Details of all prior antiretroviral therapy were
recorded at baseline. Weight, safety bloods (com-
plete blood count, electrolytes, liver enzymes, urea,
creatinine, creatine kinase, phosphate, amylase),
and adverse events were assessed every 3 months.
CD4 T-lymphocyte counts, fasting total and high
density lipoprotein (HDL) cholesterol, triglyceride,
glucose, insulin, and C-peptide levels were deter-
mined as previously described every 3 months.8
Real-time plasma HIV RNA monitoring was per-
formed at each visit using either the Roche
Amplicor Monitor assay version 1.0 (Roche Diag-
nostics, Branchburg, New Jersey, USA; lower limit
of detection 400 copies/mL plasma) or Chiron b-
DNA assay version 3 (Chiron Corporation,
Emeryville, California, USA; lower limit of detec-
tion 50 copies/mL).
Total and regional body composition was quan-
tified at screening and at weeks 24, 48, and 120 by
DEXA (Lunar DPXL; Madison, Wisconsin, USA).
Intraabdominal and extraabdominal fat areas at
the L4 vertebral level were measured at each study
site by single-cut CT.8 The validated lipodystrophy
case definition scoring (LCDS) system is based on
demographic, body composition, and metabolic
data.16 The LCDS was calculated at the completion
of the study using the available study data. A score
of   0 indicates presence of LD, with higher scores
reflecting more severe LD.17
Analysis
The main objective of the long-term follow-up
study was to assess which factors affect long-term
changes in different measures of LD. The primary
study outcomes were:
• change in limb fat from baseline at week 120 as
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• change in visceral adipose tissue (VAT) from
baseline at week 120 as assessed by CT scan.
The secondary outcomes included changes in
lean body mass (LBM), cholesterol (total and
HDL), triglycerides, CD4 count, and proportion
with detectable viral load from baseline at week
120. In addition, the change in the LCDS from
baseline to week 120 was assessed as an alternate
measure of LD in a post hoc analysis, as the scoring
system had not been developed when the present
study’s analysis plan was designed.
Analyses were limited to those patients with
DEXA and CT scans at week 120, because these
measures were required for the primary objective
of the study. Limb fat mass, VAT, and the LCDS
were used as indicators of LD severity. Compari-
sons between parameters were performed using
analysis of variance (ANOVA) and t tests. Formal
statistical comparisons between the cohorts in-
cluded and excluded from analyses were not per-
formed because statistically significant differences
would not necessarily imply clinically important
differences and vice versa. This approach is gener-
ally now accepted for comparisons of treatment
groups in terms of baseline characteristics in a ran-
domized trial, which are essentially analogous.
Univariate and multivariate linear regressions
were used to determine predictors of change in
limb fat from baseline to week 120. Initial treatment
assignment, triglycerides, and duration on differ-
ent antiretrovirals were assessed as predictors. The
final predictive model was determined using for-
ward stepwise regression. Variables with a




Eighty-one patients were screened and random-
ized into the PIILR trial. One patient randomized to
the continue group was lost to follow-up after
baseline, and three patients were lost to follow-up
after the week 48 visit. Seventy-seven patients were
followed up for 120 weeks. Of these, 45 (28 switch,
17 continue) attended for both metabolic and body
composition assessments, whereas 32 only at-
tended for metabolic assessments. This analysis
was based on only those patients with both
datasets available (Figure 1). Of the 28 patients
initially randomized to switch their PI therapy,
only 2 reinitiated PI therapy (one at week 77 and
one at week 82). Of those 17 patients initially ran-
domized to continue their PI therapy, 16 elected to
cease PI therapy after their week 24 visit and only 1
subsequently restarted at week 102. Therefore,
only 4 patients were taking PI therapy beyond the
week 24 visit in this 120-week follow-up, thereby
making this cohort of 45 patients predominantly PI
sparing (Figure 1).
Compared to the patients who did not complete
body composition analyses at the week 120 visit
(Table 1), the baseline characteristics of the studied
cohort (n = 45) showed that these patients were all
male, had a higher percentage with category C
disease, had a slightly longer duration of diag-
nosed HIV infection, were considerably heavier,
and had a slightly greater VAT.
Antiretroviral Therapy
The duration of antiretroviral treatment is sum-
marized in Table 2. All patients were naïve to the
antiretroviral drugs abacavir, nevirapine, hydrox-
yurea, and adefovir prior to enrollment in the trial.
The median study duration of adefovir and hydrox-
yurea was 29 and 32 weeks, respectively, due to the
toxicities associated with these antiretroviral agents.
Prior study exposure to ZDV was greatest (153 ± 21
weeks), followed by PIs (113 ± 5.4 weeks), and then
d4T (86 ± 6 weeks). While on study, more than half
of the patients were not taking ZDV and 60% were
randomized to stop PI, therefore the mean duration
of treatment while on study was greater for d4T.
Measures of LD
Limb fat mass and visceral adipose tissue did not
change significantly over the 120-week follow-up,
however a significant increase in the LCDS sug-
gested worsening LD over the 120 weeks (p < .001,
week 120 vs. baseline; Figure 2). The LCDS is com-
posed of body composition and metabolic param-
eters; even though independently no factor
changed significantly over time, the subtle changes
within each parameter may have combined to cre-
ate a small but statistically significant change.
Lean body mass was analyzed to ensure that fat
changes were related to LD, not general weight
changes. The lean body mass and weight did not
change over the 120 weeks.PROGRESSION OF LD WITH THYMIDINE ANALOGUE USE •M ARTIN ET AL. 195
Table 1. Baseline characteristics of included and excluded patients in the long-term follow-
up (mean ± SEM or %)
PIILR cohort not PIILR cohort with
completing body long-term follow-up
composition long-term body composition
Baseline characteristics follow-up (n = 32) (n = 45)
Age (years) 48 ± 2 45 ± 1
Male (%) 94 100
Category C disease (%) 25 36
RNA undetectable (%) 97 100
HIV duration (years) 7.1 ± 0.7 8.7 ± 0.7
Weight (kg) 71 ± 2 86 ± 1
Limb fat mass (kg) 3.9 ± 0.8 3.5 ± 0.3
VAT (cm2) 126 ± 13 136 ± 12
xxx
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Laboratory Parameters
Control of viral replication was maintained and the
lipid and glycemic parameters were not significantly
different over the 2.5-year follow-up (Table 3).
Linear Regression Analysis
Linear regression analysis showed no associa-
tion between the LD indicators and weight, triglyc-
erides, initial randomization group, or ZDV,
adefovir, or hydroxyurea usage. However, ongo-
ing d4T usage over the 120-week follow-up was
independently and significantly correlated with
greater declines in limb fat mass (-0.46 kg, p = .003)
and a greater increase in LCDS (3.19, p = .021), such
that for each year of d4T use, a decrease of 0.46 kg
limb fat mass was seen. Longer exposure to PIs
prior to trial entry was associated with a decrease
in limb fat over the 120 weeks (-0.44 kg, p = .045),
however longer usage of PIs on study was associ-
ated with an increase in limb fat over the 120 weeks
(0.82 kg, p = .007). Given the short duration of PI
use overall on the study (mean of 18 weeks within
the 2.5-year follow-up), a few patients with greater
recovery of limb fat who were reluctant to stop PIs
at week 24 may have biased this outcome.
DISCUSSION
An increasing body of evidence strongly sug-
gests that the use of thymidine analogues and/or
PIs significantly contributes to the development of
the LD syndrome.1,6,8,11,13–15 More recent studies
Table 2. HIV treatment duration prior to trial entry and total duration at the end of the follow-
up (mean ± SEM)
Duration of usage at On-study duration of usage,
baseline, weeks weeks
Drug (n = 45) (n = 45)
Protease inhibitors 113 ± 5.4 18 ± 4.0
Stavudine (d4T) 86 ± 6.1 70 ± 7.9
Zidovudine (ZDV) 153 ± 21.4 17 ± 6.1
Abacavir NA 104 ± 4.4
Nevirapine NA 108 ± 4.6
Adefovir NA 31 ± 2.5
Hydroxyurea NA 45 ± 5.5
xxx
Table 3. Laboratory parameters at baseline and week 120 (mean ± SEM)
Baseline Week 120
Parameter (n = 45) (n = 45)
CD4 T-lymphocyte count (x 106/L) 498 ± 42 490 ± 32
Total cholesterol (mmol/L) 6.6 ± 0.2 5.7 ± 0.2
HDL cholesterol (mmol/L) 0.95 ± 0.03 1.06 ± 0.05
LDL cholesterol (mmol/L) 3.60 ± 0.17 3.17 ± 0.15
Insulin (mU/L) 12.29 ± 1.41 12.53 ± 1.02
Glucose (mmol/L) 5.33 ± 0.13 5.24 ± 1.48
C-peptide (µg/L) 2.96 ± 0.21 3.67 ± 0.27
Triglycerides (mmol/L) 4.3 ± 0.5 3.8 ± 0.5
Lactate (mmol/L) 1.73 ± 0.08 1.61 ± 0.07
HIV RNA undetectable (%) 100 100
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have suggested reversibility of limb fat may occur
with cessation of thymidine analogues.18–20
LD did not improve over the 120-week follow-
up in this cohort of treated patients. When LD se-
verity was compared with various factors using
linear regression, patients with greater exposure to
d4T had reduced limb fat and a higher LCDS over
the 120 weeks. The mechanism for this effect has
been speculated to be due to nucleoside analogue–
induced mitochondrial damage.21,22 In the multi-
variate model, PI duration prior to study entry was
associated with less limb fat, but PI duration dur-
Figure 2. Body composition and lipodystrophy case definition score from baseline to 120 weeks in long-term follow-
up patients (mean ± SEM).198 HIV CLINICAL TRIALS •5 / 4•J ULY-AUGUST 2004
ing the 120-week follow-up was associated with
greater limb fat over the 120-week period. These
conflicting findings may be a reflection of the open-
label nature of the study that was conducted at a
time when PIs were thought to cause LD, that is,
those patients with less severe LD chose to remain
on their PIs, whereas those patients with more se-
vere LD chose to discontinue their PIs. Patients
were off PIs for the majority of the observation
period, so this association should be interpreted
cautiously.
LD was not reversed in this long-term strategy of
switching from PI-based HAART to predomi-
nantly PI-sparing HAART. The apparent loss of
limb fat and VAT up to week 48 may have been
related to the initial use of adefovir and hydrox-
yurea and may represent the combined adverse
effects of these drugs on LD. Hydroxyurea is
known to increase the toxicities associated with
nucleoside analogues,23,24 and adefovir is associ-
ated with weight loss.25 As most patients discontin-
ued adefovir and hydroxyurea within the first year
(due to toxicity), some recovery from these effects
may have occurred. Another possible explanation
of the loss of visceral adipose tissue seen at week 24
and 48 may be due to the impact of removing PI
therapy at week 0 for the switch arm and week 24
for the continue arm, this is explained in greater
detail in the original PIILR paper.8 However, there
are potential limitations with the analysis of this
cohort in that only 58% of original trial participants
completed the body composition analysis at 120
weeks. Also, all patients were drug experienced,
with moderate to severe LD at trial entry, a group
with the worst prognosis for LD recovery. How-
ever, our study used objective measures for
changes in LD, compared with many studies that
have utilized only subjective assessments of LD.7,26
The finding of a significant increase in the LDCS
over the 120 weeks, without significant changes in
any other primary or secondary endpoint, may be
due to subtle changes that occurred within the
LDCS calculation. The factors that comprise the
LDCS are age, sex, duration of HIV infection, CDC
classification, HDL cholesterol, anion gap,
waist:hip ratio, VAT:SAT ratio, trunk:limb ratio,
and leg fat percentage. Of these parameters, the
sex, age, duration of HIV duration, and CDC classi-
fication do not significantly vary over time. How-
ever, 4 out of the 6 metabolic and body fat param-
eters increased over time in the cohort, those being
waist:hip ratio, trunk:limb ratio, HDL cholesterol,
and anion gap.
The current backbone of antiretroviral therapy
utilizes thymidine analogues. The withdrawal of
thymidine analogues from patient’s antiretroviral
treatment has been examined in the MITOX
study.14 This 24-week study examined the effect of
switching d4T or ZDV to abacavir on HIV
lipoatrophy. There were significant increases in ob-
jectively measured limb fat, but these changes were
not apparent subjectively within this 6-month pe-
riod.14 The long-term follow-up of the MITOX
study reported that over 104 weeks the patients
who switched to abacavir at baseline increased
limb fat by 35%, whereas those who were random-
ized to remain on thymidine analogue therapy for
the first 24 weeks only improved by 13%.18 The gain
in limb fat in the abacavir group after 2 years of
follow-up was also subjectively apparent (p = .003).
Long-term exposure to PI therapy prior to trial
entry may be a surrogate marker of long-term
antiretroviral therapy. Exposure to nucleoside ana-
logues other than d4T or ZDV prior to trial entry
was not analyzed as a covariate, but this may ex-
plain the multivariate correlation reported be-
tween reduced limb fat recovery and longer prior
PI exposure. In addition, patients who elected to
remain on PI therapy while on study appear to be
those patients who had less severe LD and there-
fore saw no need to change treatment regimens.
It remains unclear whether LD is a single patho-
genic process, involving nucleoside analogue-in-
duced mitochondrial toxicity, PI-induced alter-
ations in lipid metabolism and adipocyte
apoptosis, or a mixed condition. Similarly, the role
of nonnucleosides in this process is unclear, how-
ever, numerous cross-sectional and prospective
studies have failed to implicate this group of
drugs.27,28 It is also unclear whether there is an irre-
versible component to LD. Apart from the MITOX
extension study,18 reversibility of changes of LD
has been limited or not apparent, particularly in
patients remaining on antiretroviral therapy, in a
variety of switch studies. Where reversibility in
body fat has been described, the most compelling
data come from thymidine analogue withdrawal
studies.9,11,14,15,18–20 To date, protease withdrawal
strategies have been associated with improve-
ments in lipid or glycemic parameters, but not
body fat.8 Interventions beyond switching
antiretroviral agents also need to be examined forPROGRESSION OF LD WITH THYMIDINE ANALOGUE USE •M ARTIN ET AL. 199
those patients who have limited treatment options
due to resistance to various drug classes.
CONCLUSION
In summary, features of LD did not improve
over 120 weeks after switching from a PI to a non-
PI strategy had been used. However exposure to
d4T may adversely influence the syndrome.
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